Management of moderate-to-severe plaque psoriasis with biologics: A treat-to-target position paper.
biologics
consensus recommendations
outcome measures
plaque psoriasis
systemic therapies
treat-to-target
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
04
08
2022
received:
03
05
2022
accepted:
17
08
2022
pubmed:
22
8
2022
medline:
5
10
2022
entrez:
21
8
2022
Statut:
ppublish
Résumé
Treat-to-target (T2T) recommendations for the use of systemic therapies (including biologics) in patients with moderate-to-severe plaque psoriasis have been published by a few groups of experts worldwide. However, there remains considerable variability in the choice of target severity measure and timing of milestones. To develop consensus recommendations for implementing T2T strategies for the management of moderate-to-severe plaque psoriasis using biologics. An expert group of Canadian dermatologists (the Committee) convened to develop a T2T consensus statement. They held a virtual meeting during which a preliminary set of criteria was created. These criteria were then reviewed, modified, and recirculated until unanimous agreement was achieved. The Committee agreed that defining treatment target is multidimensional and should reflect objective severity measures, as well as clinician and patient-reported outcomes. The Committee unanimously proposes a criterion-based system for determining the achievement of treatment target. The proposed T2T approach presented here provides a clinical framework for defining treatment success, measuring progress toward treatment success, recognizing when treatment modifications are warranted, and recommending treatment optimization strategies.
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15777Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
World Health Organization. Global report on psoriasis. https://apps.who.int/iris/handle/10665/204417
Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425-440.e2. doi:10.1016/j.jaad.2017.05.019
Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978-983. doi:10.1016/j.jaad.2015.02.1127
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. doi:10.1016/s0140-6736(14)61909-7
Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264-272. doi:10.1111/1346-8138.14139
Tseng J-C, Chang Y-C, Huang C-M, Hsu L-C, Chuang T-H. Therapeutic development based on the immunopathogenic mechanisms of psoriasis. Pharmaceutics. 2021;13(7):1064.
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1
Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015;19(1):22-27. doi:10.2310/7750.2014.13151
Takeshita J, Armstrong AW, Mease PJ, Gelfand JM. Treat-to-target and improving outcomes in psoriasis: a report from the GRAPPA 2014 annual meeting. J Rheumatol. 2015;42(6):1037-1040. doi:10.3899/jrheum.150128
Gordon KB, Armstrong AW, Menter MA, Wu JJ. Treating to target-a realistic goal in psoriasis? Semin Cutan Med Surg. 2018;37(2s):S44-s47. doi:10.12788/j.sder.2018.010
Lynde CW, Beecker J, Dutz J, et al. Treating to target(s) with interleukin-17 inhibitors. J Cutan Med Surg. 2019;23(2_suppl):3S-34S. doi:10.1177/1203475418824565
Smolen JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol. 2012;30((4 Suppl 73)):S2-S6.
Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9(1):5-18. doi:10.1007/s13555-018-0279-5
Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-298. doi:10.1016/j.jaad.2016.10.017
Grine L, de la Brassinne M, Ghislain PD, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020;34(4):676-684. doi:10.1111/jdv.16104
Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-1166. doi:10.1111/bjd.18333
Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235-252. doi:10.1007/s13555-020-00475-8
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-483. doi:10.1111/jdv.15340
Torres T, Tavares Bello R, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy. Eur J Dermatol. 2020;30(6):645-654. doi:10.1684/ejd.2020.3945
Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201-222. doi:10.1111/1346-8138.15196
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185. doi:10.1001/jamadermatol.2013.5264
Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585-593.e3. doi:10.1016/j.jaad.2015.06.049
Armstrong A, Jarvis S, Boehncke WH, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the clear about psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200-2207. doi:10.1111/jdv.15065
Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9(4):785-797. doi:10.1007/s13555-019-00334-1
Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235-239. doi:10.3109/09546634.2014.943687
Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487-492.
Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535. doi:10.1136/bmjopen-2018-027535
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. doi:10.1159/000250839
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057
Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645-648. doi:10.1111/jdv.12817
Torres T, Puig L. Treatment goals for psoriasis: should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155-157. doi:10.1016/j.ad.2014.10.001
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824
Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019;99(11):971-977. doi:10.2340/00015555-3245
Pascoe VL, Enamandram M, Corey KC, et al. Using the physician global assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375-381. doi:10.1001/jamadermatol.2014.3513
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997-1035. doi:10.1111/j.1365-2133.2008.08832.x
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-664. doi:10.1111/j.0022-202X.2005.23621.x
Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):17-22. doi:10.1111/j.1468-3083.2009.03563.x
Finlay AY. Skin disease disability: measuring its magnitude. Keio J Med. 1998;47(3):131-134. doi:10.2302/kjm.47.131
Herédi E, Rencz F, Balogh O, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014;15:S111-S119.
Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013;88(5):760-763. doi:10.1590/abd1806-4841.20132052
Lacour JP, Bewley A, Hammond E, et al. Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL). Dermatol Ther (Heidelb). 2020;10(5):1099-1109. doi:10.1007/s13555-020-00428-1
Loft ND, Egeberg A, Rasmussen MK, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish Nationwide Study. Acta Derm Venereol. 2019;99(13):1224-1230. doi:10.2340/00015555-3331
Manalo IF, Gilbert KE, Wu JJ. Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol. 2015;10:1086-1088.
Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73-86. doi:10.1007/s13555-019-00337-y
Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256-2269. doi:10.1007/s12325-022-02065-w
Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17(3):247-250.
Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69-78. doi:10.1007/s00403-015-1613-8
Marson J, Lebwohl M. Apremilast as an off-label therapeutic agent: a comprehensive review of safety and efficacy data in the literature for combination therapy and inflammatory dermatoses. SKIN The Journal of Cutaneous Medicine. 2021;5(3):203-227. 10.25251/skin.5.3.2
Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3-14. doi:10.1111/jdv.15218